SNS-032 (BMS-387032) is primarily investigated for its potential in cancer therapy due to its ability to inhibit cyclin-dependent kinases (CDKs). By targeting CDKs, it disrupts the cell cycle progression, particularly in cancer cells, leading to their arrest and apoptosis. This makes it a promising candidate for treating various malignancies, including hematologic cancers and solid tumors. Research has shown its efficacy in preclinical models, and it is being explored in clinical trials to assess its safety and effectiveness in humans. Additionally, its mechanism of action provides insights into developing targeted therapies for diseases characterized by abnormal cell proliferation.